NCT03591302 is a Phase 1 clinical trial of Hematopoietic cell transplantation in Immune Tolerance, sponsored by Stephan Busque.

Who is sponsoring NCT03591302?

NCT03591302 is sponsored by Stephan Busque.

What drugs are being tested in NCT03591302?

Interventions in NCT03591302: Hematopoietic cell transplantation, Total Lymphoid irradiation.

What condition does NCT03591302 study?

NCT03591302 studies Immune Tolerance.

Is NCT03591302 still recruiting?

NCT03591302 is currently status unknown. Last updated 10 May 2022.

Last reviewed 2022-05-10 · How we verify

NCT03591302

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

Status unknown Phase 1 Last updated 10 May 2022

What this trial tests

Phase 1 trial testing Hematopoietic cell transplantation in Immune Tolerance in 25 participants. Status unknown.

Timeline

13 September 2018

Primary endpoint
1 October 2025

1 October 2025

Quick facts

Lead sponsor	Stephan Busque
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	13 September 2018
Primary completion	1 October 2025
Estimated completion	1 October 2025
Sites	1 location across United States

Drugs / interventions tested

Hematopoietic cell transplantation — full drug profile →
Total Lymphoid irradiation

Conditions studied

Immune Tolerance — all drugs for Immune Tolerance →

Sponsor

Stephan Busque

Who can join

18 and older, any sex, with Immune Tolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will determine whether patients with functioning Human Leukocyte Antigen (HLA) matched kidney transplants for at least one year and who want to discontinue immunosuppressive drugs can be treated with Total Lymphoid Irradiation (TLI) and rabbit Anti-Thymocyte Globulin (rATG) and an HLA matched donor hematopoietic progenitor cell infusion such that their drugs are successfully withdrawn while maintaining normal renal function.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives.
Blein T, Ayas N, Charbonnier S, Gil A, et al · · 2025 · cited 2× · PMID 41127478 · DOI 10.3389/ti.2025.14958
HLA Type and the Effect of HLA Antibodies in Kidney, Liver, and Pancreas Transplantation: A Review.
Zarei E, Roozbeh J, Nikoupour Deylami H, Nikeghbalian S, et al · · 2026 · PMID 42080115 · DOI 10.18502/ajmb.v18i1.21042

Verify or expand the search:

Other recruiting trials for Immune Tolerance

Currently open trials in the same condition.

NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03591302 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stephan Busque
Last refreshed: 10 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03591302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing